Načítá se...
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer
RET receptor tyrosine kinase (RTK) acts as an ontogenetic driver in several human malignancies, including papillary and medullary thyroid carcinoma, lung adenocarcinoma, colorectal carcinoma, Spitzoid neoplasms, salivary gland carcinoma and chronic myeloproliferative disorders, secondary to as diver...
Uloženo v:
| Vydáno v: | Best Pract Res Clin Endocrinol Metab |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5624797/ https://ncbi.nlm.nih.gov/pubmed/28911727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beem.2017.04.013 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|